**Acute kidney injury in hospitalized cirrhotic patients: Risk factors, type of kidney injury, and survival**

Chitta Ranjan Khatua, Saroj Kanta Sahu, Dinesh Meher, Gautam Nath and Shivaram Prasad Singh

Department of Gastroenterology, Sriram Chandra Bhanja Medical College and Hospital, Cuttack, India

**Key words**
acute kidney injury, acute-on-chronic liver failure, chronic liver disease, decompensated cirrhosis.

**Accepted for publication 21 November 2020.**

**Correspondence**
Shivaram Prasad Singh, Department of Gastroenterology, Sriram Chandra Bhanja Medical College and Hospital, Cuttack 753007, Odisha, India.
Email: scb_gastro_dept@hotmail.com

**Declaration of conflict of interest:** None.

**Contribution:** Authors have contributed to study design, analysis and interpretation of data, statistical analysis, and manuscript writing.

**Abstract**

**Background and Aim:** Acute kidney injury (AKI) is a common complication of chronic liver disease (CLD). We performed a prospective study to evaluate the risk factors and spectrum of AKI among decompensated cirrhosis (DC) patients and the impact of AKI on survival.

**Methods:** This study was conducted in consecutive DC patients hospitalized in SCB Medical College between December 2016 and October 2018. AKI was defined as per ICA criteria. Demographic, clinical, and laboratory parameters and outcomes were compared between patients with and without AKI.

**Results:** A total of 576 DC subjects were enrolled, 315 (54.69%) of whom had AKI; 34% (n = 106) had stage 1A, 28% (n = 90) stage 1B, 21% (n = 65) stage 2, and 17% (n = 54) stage 3 AKI. Alcohol was the predominant cause of CLD (66.7%). In 207 (65.7%) patients, diuretic/lactulose/nonsteroidal anti-inflammatory drugs use was noted, and infection was present in 190 (60.3%) patients. Compared to those without AKI, patients with AKI had higher leucocyte count, higher serum urea and creatinine, higher Child-Turcotte-Pugh, higher Model of End-Stage Liver Disease (MELD) scores (P < 0.001), longer hospital stay, and lower survival at 28 days and 90 days (P < 0.001). Besides, in patients with stages 1A to 3 AKI, there were differences in overall survival at 28 days (P < 0.001) and 90 days (P < 0.001).

**Conclusions:** Over half of DC patients had AKI, and alcohol was the most common cause of cirrhosis in them. Use of AKI-precipitating medications was the most common cause of AKI, followed by bacterial infection. AKI patients had increased prevalence of acute-on-chronic liver failure and had prolonged hospitalization and lower survival both at 28 days and 90 days.

**Introduction**

In cirrhosis of the liver, portal hypertension leads to severe arteriovenous shunting, which results in a decrease in circulating blood volume and a compensatory activation of vasoconstrictor systems, resulting in hyperdynamic circulation and sodium and water retention and in ascites and/or dilutional hyponatremia. In advanced cirrhosis, the activation of vasoconstrictor systems may cause severe renal vasoconstriction, leading to hepatorenal syndrome (HRS), a functional renal failure associated with poor survival. Along with portal hypertension, two other factors, namely, reduction in cardiac output and systemic inflammation, are responsible for the hemodynamic alterations and renal hypoperfusion. Furthermore, systemic inflammation may also cause damage to organs other than the kidney, such as the brain, the heart, the lungs, or the liver itself, causing a multiorgan failure syndrome, which is encountered in acute-on-chronic liver failure (ACLF). As a result of multifactorial insults, patients with cirrhosis have a high prevalence of acute kidney injury (AKI), varying between 14 and 50% in patients of CLD, and this prevalence is around 20% in compensated cirrhosis and 50% in cirrhosis and ascites. Furthermore, about 50% of acute decompensated cirrhosis (DC) patients have been observed to have AKI during hospitalization, a third of which develops during the course of treatment. Even stable outpatients frequently develop AKI during follow-up.

AKI is characterized by an acute significant reduction in glomerular filtration rate (GFR), decrease in urine output, and rise in serum creatinine (Scr). It has been observed that a meager increase of 0.3 mg/dL in serum creatinine is crucial and can impact survival. As per International Club of Ascites criteria (ICA), AKI is defined as (i) an increase of Scr by 0.3 mg/dL (26.5 μmol/L) within 48 h or (ii) a percentage increase of Scr by 50% from baseline, known or presumed to have occurred within...
the prior 7 days.\textsuperscript{16} Furthermore, AKI has been classified by the ICA-AKI criteria into three stages (1–3) depending on the intensity of rise in SCr, and this staging classification correlates well with prognosis in patients with cirrhosis,\textsuperscript{17,18} with stages 2 and 3 having worse prognosis compared with stage 1.\textsuperscript{1,4,8,9,10,17,19} Recently, stage 1 has been further subdivided into two subgroups on the basis of serum levels of creatinine (SCr): stage 1A (SCr < 1.5 mg/dL) and stage 1B (SCr ≥ 1.5 mg/dL), and this sub-classification is justified by the differential outcomes.\textsuperscript{11,20}

The most common precipitants of AKI are prerenal injury (70%) and intrinsic renal causes (30%), followed by postrenal factors (<1%).\textsuperscript{10,21} It has been reported that the presence of AKI in DC or ACLF patients adversely affects survival; hence, early recognition of AKI causes and its treatment is crucial for improving outcome.\textsuperscript{22–25} For this, a thorough history and careful physical examination are crucial to evaluate causes for AKI, such as ongoing gastrointestinal losses (diarrhea/vomiting) leading to hypovolemia and hypotension, use of medications (i.e. diuretics, nonsteroidal anti-inflammatory drugs [NSAIDs], angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, vasodilators, and aminoglycoside antibiotics), and presence of cellulitis or other infections. An appropriate workup, such as obtaining pan cultures and chest radiography, urinalysis and urine microscopy, and urine biomarkers estimation, should be performed to detect infection and intrarenal injury.\textsuperscript{16,21,26} Renal ultrasound is necessary to rule out postrenal injury.

The present study was conducted to evaluate the risk factors and spectrum of AKI among DC patients and the impact of AKI on the survival of these patients.

\textbf{Methods}

\textbf{Study design.} A prospective study was carried out in consecutive DC patients hospitalized in the Gastroenterology Department, SCB Medical College between December 2016 and October 2018; they were screened for AKI as per ICA-AKI criteria.\textsuperscript{16}

Demographic, clinical, and laboratory parameters and type of kidney injury were recorded on admission; the risk factors for AKI were evaluated, and survival was compared between patients with and without AKI and also among different stages of AKI. Survival was compared during hospitalization and also at 28 and 90 days.

Patients were meticulously assessed for known risk factors causing AKI and were managed according to the standard of care. All drugs precipitating AKI were stopped; intravascular hypovolemic condition was corrected with intravenous saline; and variceal bleeding was treated with blood transfusions and intravenous terlipressin, followed by endotherapy. Intravenous albumin was used for initial volume expansion for 48 h, and patients with volume-nonresponsive AKI fulfilling the criteria for HRS were treated with intravenous albumin and terlipressin or noradrenaline; hemodialysis was planned when required. Patients with bacterial infection received empirical intravenous antibiotics and albumin; the antibiotics were later changed according to culture and sensitivity result. In the presence of septic shock, noradrenaline infusion was used.\textsuperscript{16,27,28}

Furthermore, all cirrhotic patients were screened for the presence of ACLF as per the criteria of APASL, EASL-CLIF Consortium, or both. ACLF has been defined differently by various learned hepatology societies. As per the APASL consensus, “ACLF is an acute hepatic insult manifesting as jaundice (serum bilirubin ≥ 5 mg/dL (85 μmol/L) and coagulopathy (INR ≥ 1.5 or prothrombin activity <40%) complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease or cirrhosis”, and is associated with a high 28-day mortality.\textsuperscript{79} However, the AASLD and EASL working group defines ACLF as “Acute deterioration of pre-existing chronic liver disease usually related to a precipitating event and associated with increased mortality at 3 months due to multi-system organ failure”.\textsuperscript{30}

\textbf{Inclusion criteria.} All DC patients, diagnosed on the basis of clinical findings, laboratory test results, endoscopy, and radiologic imaging, with a SCr report within the previous 7 days were included in the study.

\textbf{Exclusion criteria.} Patients with chronic kidney disease, structural kidney disease, hepatocellular carcinoma, other malignancies, and cardiopulmonary diseases were excluded from the study.

The study was thoroughly explained to patients satisfying the inclusion criteria, and these patients were included if they agreed and signed an informed consent form and were followed up for 90 days.

\textbf{Primary and secondary outcomes.} Survival at 28 days was defined as the primary end-point, while that at 90 days served as the secondary end-point for our survival analysis. Duration of hospital stay was the other secondary end-point for comparing DC patients with and without AKI at admission.

\textbf{Statistical methods.} Demographic, clinical, and laboratory parameters and outcomes were compared between patients with and without AKI. Normally distributed continuous variables were reported as mean and standard deviation and compared using Student t test. Nonnormally distributed continuous variables were reported as median and interquartile range and compared using the Mann–Whitney U test. Categorical variables were reported as proportions and compared using the chi-square test or Fisher exact test, as appropriate. The 28-day and 90-day survival was estimated by the Kaplan–Meier method and compared by means of the log-rank test. Receiver operating characteristic curve (AUROC) analysis for prognostic parameters like admission serum urea, serum creatinine, presence of infection, variceal bleeding, gastrointestinal losses, and reversal of creatinine was carried out to evaluate the impact on survival both at 28 days and 90 days. All tests were two-tailed, and $P$ values <0.05 were considered significant. A statistical analysis was performed using SPSS statistical package, version 20.0 (IBM Corp, Armonk, NY, USA).

Ethical clearance has been obtained from the Institutional Ethics Committee, SCB Medical College, Cuttack 753007, Odisha, Regd. No.ECR/84/Inst/OR/2013.
Results

A total of 613 DC patients were admitted; 37 patients were subsequently excluded because they either did not meet the inclusion criteria or were lost to follow-up. Of the remaining 576 patients, 315 (54.69%) had AKI and were enrolled in the study. Alcohol was not only the most common cause of underlying cirrhosis (58.7%) overall but was the most common cause of cirrhosis in patients with AKI (66.7%) (Table 1). In patients with AKI, other less common causes of cirrhosis were hepatitis B (HBV) or hepatitis C virus (HCV) infection (18.41%), NASH-related cirrhosis (5.08%), and other miscellaneous causes (9.84%) (Fig. 1a). AKI patients had used AKI-precipitating drugs (such as diuretic/lactulose/NSAIDS) more frequently (65.7% vs 32.2%; P < 0.001) and were more often admitted with associated bacterial infections (60.3% vs 32.2%; P < 0.001). However, the prevalence of variceal bleeding, diarrhea, and/or vomiting was comparable between patients with and without AKI. AKI patients were more often males (59%) and older (49.76 vs 47.66; P = 0.043). Furthermore, patients with AKI had a higher total leucocyte count (8600 vs 7200; P < 0.001), total bilirubin (3.80 vs 2.30; P < 0.001), serum creatinine (1.70 vs 0.90; P < 0.001), serum urea (49 vs 22; P < 0.001), INR (1.79 vs 1.55; P < 0.001), serum potassium (4.20 vs 4.00; P = 0.018), and other variables as given in Table 1.

Table 1  Comparison of baseline characteristics and acute kidney injury (AKI) precipitants at admission between patients with and without AKI

| Sl. no | Parameters | Patients without AKI (n = 261) | Patients with AKI (n = 315) | P value |
|-------|------------|-------------------------------|-----------------------------|---------|
| 1     | Age (mean ± SD) | 47.66 ± 12.69 | 49.76 ± 11.87 | 0.043 |
| 2     | Gender: Male (%) | 198 (41%) | 285 (59%) | <0.001 |
| 3     | BMI (kg/m²) (mean ± SD) | 21.23 ± 3.70 | 21.82 ± 4.0 | 0.069 |
| 4     | MAP (mmHg) (mean ± SD) | 85.32 ± 8.42 | 83.62 ± 11.23 | 0.039 |
| 5     | Etiology of cirrhosis (% Alcohol) | 128 (49.1%) | 210 (66.7%) | <0.001 |
| 6     | Serum creatinine (mg/dL) (Median [IQR]) | 0.90 (0.80–1.0) | 1.70 (1.30–2.40) | <0.001 |
| 7     | Urea (mg/dL) (Median [IQR]) | 49 (28–18) | 48 (35–79) | <0.001 |
| 8     | Serum bilirubin (total in mg/dL) (Median [IQR]) | 2.30 (1.10–4.40) | 3.80 (1.50–7.60) | <0.001 |
| 9     | INR (Median [IQR]) | 1.55 (1.31–1.84) | 1.79 (1.46–2.36) | <0.001 |
| 10    | Serum protein (g/dL) (Mean ± SD) | 6.50 ± 0.90 | 6.48 ± 2.02 | 0.878 |
| 11    | Serum albumin (g/dL) (Mean ± SD) | 2.72 ± 0.49 | 2.64 ± 0.49 | 0.041 |
| 12    | Serum sodium (mEq/L) (Mean ± SD) | 134.65 ± 13.06 | 132.58 ± 10.99 | 0.043 |
| 13    | Serum potassium (mEq/L) (Median [IQR]) | 4.00 (3.50–4.30) | 4.20 (3.70–4.90) | 0.018 |
| 14    | SAAG (Mean ± SD) | 2.28 ± 0.52 | 2.19 ± 0.53 | 0.041 |
| 15    | Total leucocyte count (10³ cells/dL) (Median [IQR]) | 7200 (6200–9200) | 8600 (6800–12 000) | <0.001 |
| 16    | Urine Sodium (mEq/L) (Median [IQR]) | 40.20 (22.00–76.93) | 35.20 (20.00–65.00) | 0.479 |
| 17    | Vascular bleeding (%) | 140 (53.6%) | 147 (46.7%) | 0.096 |
| 18    | Diarrhea and/or vomiting (%) | 93 (35.6%) | 95 (30.2%) | 0.163 |
| 19    | Infection (%) | 84 (32.2%) | 190 (60.3%) | <0.001 |
| 20    | Drugs precipitating AKI (%) | 81 (31.1%) | 207 (65.7%) | <0.001 |

BMI, body mass index; CTP, Child-Turcotte-Pugh; INR, International Normalized Ratio; IQR, interquartile range; MAP, mean arterial pressure; MELD, model for end-stage liver disease; SAAG, serum-ascites albumin gradient; SD, standard deviation; UNOS, The United Network for Organ Sharing.
Table 2  Comparison of indices of severity of liver disease and outcomes at admission between patients with and without acute kidney injury (AKI)

| Sl. no | Parameters                      | Patients without AKI (n = 261) | Patients with AKI (n = 315) | P value |
|--------|---------------------------------|---------------------------------|-----------------------------|---------|
| 1      | MELD (UNOS) (Mean ± SD)         | 15.47 ± 7.70                    | 24.70 ± 9.03                | <0.001  |
| 2      | MELD (Na+) (Mean ± SD)          | 18.02 ± 6.12                    | 26.69 ± 8.59                | <0.001  |
| 3      | CTP score (Mean ± SD)           | 10.08 ± 2.30                    | 11.42 ± 2.42                | <0.001  |
| 4      | Child class (%)                 | A 9 (3.45%)                     | 4 (1.27%)                   | <0.001  |
|        |                                 | B 102 (39.1%)                   | 63 (20%)                    |         |
|        |                                 | C 150 (57.5%)                   | 248 (78.7%)                 |         |
| 5      | ACLF (APASL) (n = 154)          | 44 (28.6%)                      | 110 (71.4%)                 | <0.001  |
| 6      | ACLF (EASL-CLIF Consortium) (n = 232) | 44 (19%)                   | 188 (81%)                   | <0.001  |
| 7      | ACLF (APASL and EASL-CLIF Consortium) (n = 110) | 20 (18.2%)           | 90 (81.8%)                   | <0.001  |
| 8      | Duration of hospital stay (Median [IQR]) | 4 (3–5)                  | 6 (4–8)                    | <0.001  |
| 9      | Death during hospitalization     | 7 (2.7%)                       | 56 (17.8%)                  | <0.001  |
| 10     | 28-day survival (%)             | 232 (88.9%)                     | 210 (66.7%)                 | <0.001  |
| 11     | 90-day survival (%)             | 197 (75.5%)                     | 140 (44.4%)                 | <0.001  |
| 12     | HR of mortality during hospitalization | HR, 1.506; 95% CI, 1.362–1.666 | <0.001                     |
| 13     | HR of mortality at 28 days       | HR, 1.430; 95% CI, 1.320–1.549  | <0.001                     |
| 14     | HR of mortality at 90 days       | HR, 1.384; 95% CI, 1.290–1.484  | <0.001                     |

ACLF, acute-on-chronic liver failure; APASL, Asian Pacific Association for the Study of the Liver; EASL-CLIF Consortium, European Association for the Study of the Liver Chronic Liver Failure Consortium; HRS, hepatorenal syndrome; IQR, interquartile range; HR, hazard ratios.

P < 0.001) and EASL-CLIF Consortium criteria (59.7 vs 16.9%; P < 0.001) individually and also as per both criteria combined (81.8 vs 18.2%; P < 0.001). Patients with AKI also had a longer hospital stay (6 days vs 4 days; P < 0.001) (Tables 1 and 2), increased death during hospitalization (17.8 vs 2.7%; P < 0.001), and decreased survival both at 28 days (66.7 vs 88.9%)

Table 3  Comparison of baseline characteristics and acute kidney injury (AKI) precipitants between patients with AKI stages 1A, 1B, 2, and 3, staged according to level of serum creatinine at admission

| Sl. no | Parameters                      | Patients with AKI stage 1A (n = 106) | Patients with AKI stage 1B (n = 90) | Patients with AKI stage 2 (n = 65) | Patients with AKI stage 3 (n = 54) | P value |
|--------|---------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|---------|
| 1      | Age (Mean ± SD)                 | 49.73 ± 11.75                     | 50.88 ± 12.90                     | 48.33 ± 12.63                     | 49.66 ± 9.19                     | 0.628   |
| 2      | Gender: Male (%)                | 96 (34.4%)                        | 81 (28.4%)                        | 58 (20.4%)                        | 48 (16.8%)                       | 0.854   |
| 3      | BMI (kg/m²) (Mean ± SD)         | 22.00 ± 3.73                      | 22.4 ± 4.11                       | 21.10 ± 4.90                      | 21.62 ± 2.96                     | 0.331   |
| 4      | MAP (mmHg) (Mean ± SD)          | 85.99 ± 9.61                      | 83.88 ± 11.33                     | 82.88 ± 9.75                      | 79.44 ± 12.84                    | 0.005   |
| 5      | Etiology of cirrhosis (Alcohol [%]) | 68 (42.2%)                      | 56 (62.2%)                        | 47 (73.2%)                        | 39 (72.2%)                       | 0.659   |
| 6      | Serum creatinine (mg/dL) (Mean ± SD) | 1.26 ± 0.09                      | 1.69 ± 0.15                       | 2.39 ± 0.33                       | 4.38 ± 1.61                      | <0.001  |
| 7      | Urea (mg/dL) (Median [IQR])     | 33 (25–43)                        | 46.5 (37–65)                      | 65 (51–94)                        | 109 (85–133)                     | <0.001  |
| 8      | Serum bilirubin (total mg/dL) (Median [IQR]) | 2.7 (1.25–5.5)                 | 3.9 (1.5–9.5)                     | 5.5 (1.45–11.65)                  | 4.65 (1.59–9.50)                 | <0.001  |
| 9      | INR (Median [IQR])              | 1.72 (1.47–2.13)                  | 1.74 (1.39–2.37)                  | 1.89 (1.47–2.36)                  | 2.17 (1.57–3.16)                 | <0.001  |
| 10     | Serum protein (g/dL) (Mean ± SD) | 6.42 ± 0.86                       | 6.84 ± 3.39                       | 6.24 ± 0.98                       | 6.32 ± 0.87                      | 0.244   |
| 11     | Serum albumin (g/dL) (Mean ± SD) | 2.75 ± 0.51                       | 2.62 ± 0.53                       | 2.60 ± 0.43                       | 2.47 ± 0.43                      | 0.006   |
| 12     | Serum sodium (mEq/L) (Mean ± SD) | 135.36 ± 7.78                     | 132.07 ± 15.54                    | 132.43 ± 8.66                     | 128.19 ± 7.95                    | 0.001   |
| 13     | Serum potassium (mEq/L) (Median [IQR]) | 4.20 (3.88–4.70)                | 4.20 (3.50–4.92)                  | 4.10 (3.20–4.80)                  | 4.65 (3.78–5.33)                 | 0.429   |
| 14     | SAAG (Mean ± SD)                | 2.30 ± 0.55                       | 2.21 ± 0.58                       | 2.13 ± 0.46                       | 2.03 ± 0.44                      | 0.014   |
| 15     | Total leucocyte count (10^3 cells/dL) (Median [IQR]) | 8400 (6400–10 250)              | 8650 (7150–12 350)                | 9600 (7200–12 700)                | 9800 (7800–12 650)               | 0.020   |
| 16     | Urine sodium (mEq/L) (Median [IQR]) | 34 (19.25–64.83)                | 42 (22–74.25)                     | 30.50 (15.30–62.55)               | 41.95 (19.65–72.48)              | 0.217   |
| 17     | Variceal bleeding (%)           | 59 (55.7%)                        | 36 (40%)                          | 31 (47.7%)                        | 21 (38.9%)                       | 0.094   |
| 18     | Diarrhea and/or vomiting (%)    | 32 (30.2%)                        | 23 (25.6%)                        | 23 (35.4%)                        | 17 (31.5%)                       | 0.616   |
| 19     | Infection (%)                   | 43 (40.6%)                        | 54 (60%)                          | 47 (72.3%)                        | 46 (85.2%)                       | <0.001  |
| 20     | Drugs precipitating AKI (%)      | 68 (64.2%)                        | 55 (61.1%)                        | 42 (65.6%)                        | 42 (77.8%)                       | 0.214   |

BMI, body mass index; CTP, Child-Turcotte-Pugh; INR, International Normalized Ratio; IQR, interquartile range; MAP, mean arterial pressure; MELD, model for end-stage liver disease; SAAG, serum-ascites albumin gradient; SD, standard deviation; UNOS, The United Network for Organ Sharing.
P < 0.001) and 90 days (44.4 vs 75.5%; P < 0.001). Of AKI patients, 62% (n = 196) had stage 1, 21% (n = 65) stage 2, and 17% (n = 54) had stage 3 AKI, and of the stage 1 AKI patients, 54.08% (n = 106) had stage 1A, and 45.92% (n = 90) had stage 1B AKI. On comparison of AKI precipitants, only infection was more commonly associated with higher grades of AKI (40.6% in stage 1A, 60% stage 1B, 72.3% stage 2, and 85.2% stage 3; P < 0.001) (Fig. 1b); all other known precipitants were comparable. Besides, it was also observed that there was increased prevalence of HRS in patients with higher grades of AKI (P < 0.001) (Table 3). AKI patients also had higher prevalence of ACLF as per the EASL-CLIF Consortium criteria (P < 0.001) and combined criteria (P < 0.001) but not as per APASL criteria (Table 3 and 4). It was further observed that higher-grade AKI patients had decreased reversal of AKI, increased median duration of hospital stay (P < 0.001), and increased hospital mortality (P < 0.001) (Table 4), and the hazard ratios for mortality were significant in patients with AKI during hospitalization (hazard ratio [HR], 1.506; 95% confidence interval [CI], 1.362–1.666; P < 0.001) and also at 28 days (HR, 1.430; 95% CI, 1.320–1.549; P < 0.001) and 90 days (HR, 1.384; 95% CI, 1.290–1.484; P < 0.001). Furthermore, they had stage-wise decreased survival both at 28 days (P < 0.001) and 90 days (P < 0.001) from stage 1A to stage 3 AKI (Table 4). Kaplan–Meier survival analysis showed significant differences in survival between AKI stages 1A, 1B, 2, and 3 and without AKI, both at 28 days (log-rank P value < 0.001) and 90 days (log-rank P value < 0.001) (Fig. 2a,b). ROC curve analysis showed admission serum creatinine (AUC 28 days; 0.69, AUC 90 days; 0.66, 95% CI), serum urea (AUC 28 days; 0.65, AUC 90 days; 0.62, 95% CI), and presence of infection (AUC 28 days; 0.56, AUC 90 days; 0.57, 95% CI), were able to predict death both at 28 days and 90 days (Fig. 2c,d), while reversal of AKI was a predictor of increased survival both at 28 days (AUC of 0.26, 95% CI, and 0.19–0.31) and 90 days (AUC of 0.33, 95% CI, and 0.27–0.39) (Table 4).

### Discussion

In our study, the prevalence of AKI in DC patients was 54.69%, and alcohol was the most common underlying etiology of cirrhosis irrespective of AKI (Table 1). Use of AKI-precipitating medications was commonly seen, followed by presence of bacterial infection. In the present study, a greater proportion of patients was admitted with early stage 1 AKI (AKI 1A) (Table 4). However, increased prevalence of ACLF (as per EASL-CLIF Consortium and combined criteria) was seen in patients with higher grades of AKI from stage 1A to stage 3 (P < 0.001), but not as per APASL criteria (P = 0.110) (Table 4). The difference in ACLF prevalence as per different criteria was possibly because of the difference in defining criteria, with only the AASLD-EASL working group including serum creatinine level as ACLF-defining criteria.

A comparison of the AKI prevalence and profile of our patients with other studies showed significant differences, which are demonstrated in Table 5. The prevalence of AKI in other studies varies between 46 and 67%, akin to our study (54.6%) (Table 5). In our patients, alcohol was the most common underlying etiology of cirrhosis. In contrast, de Carvalho et al. (53.9%) and Montoliu et al. (51.7%) have reported

### Table 4

Comparison of indices of severity of liver disease and outcomes between patients with acute kidney injury (AKI) stages 1A, 1B, 2, and 3, staged according to level of serum creatinine at admission

| Sl. no | Parameters | Patients with AKI stage 1A (n = 106) | Patients with AKI stage 1B (n = 90) | Patients with AKI stage 2 (n = 65) | Patients with AKI stage 3 (n = 54) | P value |
|-------|------------|--------------------------------------|-------------------------------------|----------------------------------|----------------------------------|---------|
| 1     | MELD (UNOS) (Mean ± SD) | 18.79 ± 5.46 | 23.46 ± 7.12 | 28.21 ± 8.41 | 34.11 ± 8.73 | <0.001 |
| 2     | MELD (Na') (Mean ± SD) | 21.26 ± 5.96 | 25.98 ± 7.21 | 29.84 ± 7.82 | 34.74 ± 8.25 | <0.001 |
| 3     | CTP score (Mean ± SD) | 10.63 ± 2.26 | 11.34 ± 2.29 | 11.89 ± 2.38 | 12.55 ± 2.26 | <0.001 |
| 4     | Child class (%) | A 1 (0.9%) | 3 (3.3%) | 0 (0%) | 0 (0%) | 0.143 |
|       |             | B 27 (25.5%) | 18 (20%) | 12 (18.5%) | 6 (11.1%) |         |
|       |             | C 78 (73.6%) | 69 (76.7%) | 53 (81.5%) | 48 (88.9%) |         |
| 5     | HRS (%) | 6 (6.7%) | 24 (26.7%) | 36 (55.4%) | 38 (70.4%) | <0.001 |
| 6     | ACLF (APASL) (n = 110) | 28 (25.4%) | 32 (29.1%) | 27 (24.6%) | 23 (20.9%) | 0.110 |
| 7     | ACLF (EASL-CLIF Consortium) (n = 188) | 28 (14.9%) | 49 (26.1%) | 61 (32.4%) | 50 (26.6%) | <0.001 |
| 8     | ACLF (APASL and EASL-CLIF Consortium) (n = 90) | 14 (15.6%) | 26 (28.9%) | 27 (30%) | 23 (25.6%) | <0.001 |
| 9     | Reversal of AKI (%) | 90 (84.9%) | 57 (63.3%) | 28 (43.1%) | 12 (22.2%) | <0.001 |
| 10    | Duration of hospital stay (Median [IQR]) | 4 (3–5) | 5 (4–7) | 7 (6.5–11) | 8 (6–11) | <0.001 |
| 11    | Death during hospitalization | 2 (1.9%) | 15 (16.7%) | 17 (26.2%) | 22 (40.7%) | <0.001 |
| 12    | 28-day survival (%) | 88 (83%) | 63 (70%) | 38 (58.5%) | 21 (38.9%) | <0.001 |
| 13    | 90-day survival (%) | 65 (61.3%) | 40 (44.4%) | 20 (30.8%) | 15 (27.8%) | <0.001 |

*Significant when compared between AKI stages 1A and 1B.
*Significant when compared between AKI stages 1A and 2.
*Significant when compared between AKI stages 1 and 3.
*Significant when compared between AKI stages 1B and 2.
*Significant when compared between AKI stages 1A and 3.
*Significant when compared between AKI stages 2 and 3.

AFLC, acute-on-chronic liver failure; APASL, Asian Pacific Association for the Study of the Liver; EASL-CLIF Consortium, European Association for the Study of the Liver Chronic Liver Failure Consortium; HRS, hepatorenal syndrome; IQR, interquartile range.
chronic viral hepatitis as the most common etiology.\textsuperscript{7,18} The prevalence of different stages of AKI in our study is not different from the reported prevalence by Belcher et al., Huelin et al., and de Carvalho et al. (stage 1 AKI [41.9–68%], stage 2 AKI [2.5–29%], stage 3 AKI [1.5–23%]).\textsuperscript{10,11,18} However, AKI 1A (106, 54%) and AKI 1B (90, 46%) patients were equally

Figure 2 (a) Kaplan–Meier survival curves showed significant differences in survival between patients with acute kidney injury (AKI) 1A, AKI 1B, AKI 2, and AKI 3 and those without acute kidney injury at 28 days (log-rank $P$ value $<$0.001). (---) without AKI; (----) AKI 1A; (-----) AKI 1B; (-----) AKI 2; (-----) AKI 3. (b) Kaplan–Meier survival curves showed significant differences in survival between patients with acute kidney injury (AKI) 1A, AKI 1B, AKI 2, and AKI 3 and those without acute kidney injury at 90 days (log-rank $P$ value $<$0.001). (---) without AKI; (----) AKI 1A; (-----) AKI 1B; (-----) AKI 2; (-----), AKI 3. (c) Receiver operating characteristic curves (AUROC) for prognostic parameters for 28-day survival in patients with AKI. (---), Admission serum urea; (-----), admission serum creatinine; (----), infection; (-----), variceal bleeding; (-----), diarrhoea/vomiting; (-----), normal creatinine/reversal of AKI; (-----), reference line. (d) Receiver operating characteristic curves (AUROC) for prognostic parameters for 90-day survival in patients with AKI.
Table 5 Comparison of acute kidney injury (AKI) prevalence and profile of our patients along with etiopathogenic factor and comorbidity

| Period of study | Total patients | Prevalence of AKI | Prevalence of bacterial infection | Prevalence of AKI-precipitating drugs used | Hospital mortality | Mortality at 1 month | Mortality at 3 months |
|-----------------|----------------|-------------------|----------------------------------|------------------------------------------|-------------------|---------------------|---------------------|
| 2010–2012       | 337            | 166 (49.3%)       | 71 (57.7%)                       | 43 (34.1%)                               | 34%               | 175 (55.6%)         |
| 2011–2015       | 547            | 290 (53%)         | 55 (19%)                         | 73 (81.1%)                               | 48%               | 105 (33.3%)         |
| 1977–2010       | 8088           | 3946 (49%)        | 152 (52%)                        | 66 (72.9%)                               | 55 (44.7%)        |                      |
| 2003–2007       | 198            | 129 (49%)         | 204 (71%)                        | 79 (64%)                                 | 56 (17.8%)        |                      |
| 1998–2002       | 263            | 123 (45%)         | 197 (68%)                        | 80 (65%)                                 |                   |                      |
| 2016            | 351            | 91 (48%)          | 3 (1.5%)                         | 47 (39%)                                 | 75 (25%)          |                      |
| 2016–2018       | 576            | 19 (15.4%)        | 196 (62.2%)                      | 19 (15.4%)                               |                   |                      |

† Prevalence was 6% by Belcher.

††† † Prevalence of bacterial infection.

†† † † † † † † Hospital mortality when AKI-precipitating drugs used.

†† † † † † † † Mortality at 1 month when AKI-precipitating drugs used.

††† † † † † † † Mortality at 3 months when AKI-precipitating drugs used.

† No data available.

CLD, chronic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus.

distributed in our cohort, in contrast to the study by Huelin et al. (AKI 1A [58, 29.4%] and AKI 1B [139, 70.6%]), in which over two-thirds had AKI stage 1B. Variceal bleeding was much more common in our patients (46.7%) in comparison to other studies (5–34.1%). Furthermore, de Carvalho et al. observed the use of AKI-precipitating medications in 81.1% of cases in contrast to 65.7% of cases in our study. In our study, the prevalence of infection was 60.3%, whereas the reported prevalence was 6% by Belcher et al., 71% by Huelin et al., and 72.9% by de Carvalho et al. (Table 5). Surprisingly, the hospital mortality rate in our study was much lower—only 17.8%—in contrast to 52.7% reported by de Carvalho et al. and 44.7% by Shetty et al. In addition, the 28-day mortality rate in our AKI patients was 33.3%, which is similar to Wong et al. (34%) but much lower than the mortality rate reported by de Carvalho et al. (67%).

Our study clearly demonstrated that the reversal of AKI was negatively associated with mortality (Fig. 2c,d), which implies that patients should be aggressively treated till reversal of renal failure, and if necessary, early renal replacement therapy with hemodialysis should be arranged for a better outcome. This is especially crucial in the light of the earlier observation that the pretransplant serum creatinine level affects postliver transplantation survival.

During the selection of patients, we excluded patients with preexisting chronic kidney disease and structural kidney disease. On the subject of different forms of AKI, we ruled out acute tubular necrosis (ATN) and postrenal AKI on the basis of urinary examination and ultrasonography. However, identifying and excluding patients with intrinsic renal disease in this fashion, due to a lack of facilities for kidney biopsy and estimation of urine biomarkers at our center, was a distinct limitation of the study.

In the present study, over half of the DC patients had AKI, and in two-thirds of them, alcohol was the underlying etiology of cirrhosis. Furthermore, about two-thirds were admitted with stage 1 AKI, and more than half of them had early stage 1 AKI. There was stage-wise prolonged hospitalization and decreased survival of patients both at 28 days and 90 days, indicating the need for early detection and timely aggressive intervention for better survival of cirrhotic patients.

Besides, reversal of AKI resulted in increased survival both at 28 days and 90 days. Thus, in DC patients, AKI should be treated aggressively at the earliest till its reversal. An interesting observation in our study was the association of AKI with ACLF diagnosed on the basis of EASL-CLIF Consortium criteria but not on the basis of APASL criteria. This is because of the mechanistic etiological association between the two groups. Presence of AKI could well be deemed a surrogate marker of ACLF diagnosed by the EASL-CLIF Consortium criteria.

Regarding precipitants, use of medications was the most common AKI precipitant in our study, but bacterial infections were also significantly associated with higher grades of AKI. Besides, multiple precipitants of AKI were commonly seen in our study.

Acknowledgments

We express our deepest gratitude to all the patients and their family members for their willing cooperation.

References

1. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988; 8: 1151–7.
2 Arroyo V, Ginès P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996; 23:164-76.

3 Martín-Llñí M, Guevara M, Torre A et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology. 2011; 140:488-496.e4.

4 Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decomposition and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J. Hepatol. 2015; 63:1272-84.

5 Claria J, Stauber RE, Coenraad MJ et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology. 2016; 64:1249-64.

6 Piano S, Romano A, Di Pascoli M, Angeli P. Why and how to measure renal function in patients with liver disease. Liver Int. 2017; 37 (Suppl. 1): 116-22.

7 Montoliu S, Ballesté B, Planas R et al. Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin. Gastroenterol. Hepatol. 2010; 8:616-22.

8 Fagundes C, Barreto R, Guevara M et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J. Hepatol. 2013; 59:474-81.

9 Piano S, Rosi S, Maresio G et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J. Hepatol. 2013; 59:482-9.

10 Belcher JM, Garcia-Tsao G, Sanyal AJ et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2013; 57:753-62.

11 Huelin P, Piano S, Sola E et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure. Clin. Gastroenterol. Hepatol. 2017; 15:438-445.e5.

12 Tsiern CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013; 62:131-7.

13 Bellomo R, Ronco C, Kellum J, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative working group. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care. 2004; 8:R204-12.

14 Wong F, Nadim MK, Kellum JA et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011; 60:702-9.

15 Russ KB, Stevens TM, Singal AK. Acute kidney injury in patients with cirrhosis. J. Clin. Transl. Hepatol. 2015; 3:195-204.

16 Angeli P, Ginès P, Wong F et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J. Hepatol. 2015; 62:968-74.

17 Fede G, D’Amico G, Arvaniti V et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J. Hepatol. 2012; 56:810-18.

18 de Carvalho JR, Villela-Nogueira CA, Luiz RR et al. Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites. J. Clin. Gastroenterol. 2012; 46:e21-6.

19 Angeli P, Rodríguez E, Piano S et al. Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decomposition of cirrhosis. Gut. 2015; 64:1616-22.

20 Khatua CR, Sahu SK, Barik RK et al. Validation of International Club of Ascites subclassification of stage 1 acute kidney injury in chronic liver disease. JGH Open. 2019; 3:290-4.

21 Ginès P, Schrier RW. Renal failure in cirrhosis. N. Engl. J. Med. 2009; 361:1279-90.

22 Khatua CR, Panigrahi S, Mishra D et al. Acute kidney injury at admission is a better predictor of mortality than persistence at 48 h in patients with acute-on-chronic liver failure. J. Clin. Transl. Hepatol. 2018; 6:396-401.

23 Nassar Junior AP, Farias AQ, D’ Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and metaanalysis. PLoS One. 2014; 9:e107466.

24 Hiremath SB, Srinivas LD. Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a metaanalysis. Indian J. Pharm. 2013; 45:54-60.

25 Latt N, Alachkar N, Gurakar A. Hepatitis C virus and its renal manifestations: a review and update. Gastroenterol. Hepatol. 2012; 8:434-45.

26 Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008; 48:2064-77.

27 Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J. Hepatol. 2017; 66:849-59.

28 Piano S, Brocca A, Mareso S, Angeli P. Infections complicating cirrhosis. Liver Int. 2018; 38 (Suppl. 1):126-33.

29 Sarin SK, Kumar A, Kedarisetty CK et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol. Int. 2014; 8:453-71.

30 Moreau R, Jalan R, Ginès P et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decomposition of cirrhosis. Gastroenterology. 2013; 144:1426-37,1437.e1-1437.e9.

31 Shetty S, Nagaraju SP, Shenoy S et al. Acute kidney injury in patients with cirrhosis of liver: clinical profile and predictors of outcome. Indian J. Gastroenterol. 2018; 37:248-54.

32 Wong F, O’Leary JG, Reddy KR et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology. 2013; 145:1280-8.e1.

33 Sharma P, Scahubel DE, Guidinger MK, Merion RM. Effect of pretransplant serum creatinine on the survival benefit of liver transplantation. Liver Transpl. 2009; 15:1808-13.